MDxHealth (NASDAQ:MDXH) Raised to "Hold" at Wall Street Zen

Wall Street Zen upgraded shares of MDxHealth (NASDAQ:MDXH - Free Report) to a hold rating in a report issued on Saturday.

MDxHealth Price Performance

NASDAQ MDXH traded up $0.01 during mid-day trading on Friday, hitting $2.13. The stock had a trading volume of 73,442 shares, compared to its average volume of 86,211. The stock has a market capitalization of $100.49 million, a price-to-earnings ratio of -1.40 and a beta of 1.32. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 1.45. MDxHealth has a twelve month low of $1.35 and a twelve month high of $3.50. The firm's 50 day moving average is $1.69 and its 200 day moving average is $1.85.

MDxHealth (NASDAQ:MDXH - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.06). The company had revenue of $24.29 million during the quarter, compared to analysts' expectations of $22.62 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. Equities research analysts forecast that MDxHealth will post -1.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

Several institutional investors have recently bought and sold shares of MDXH. Renaissance Technologies LLC boosted its stake in MDxHealth by 715.2% in the fourth quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock valued at $292,000 after acquiring an additional 108,000 shares during the period. Perkins Capital Management Inc. lifted its position in shares of MDxHealth by 31.6% in the fourth quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company's stock worth $2,331,000 after buying an additional 236,100 shares during the last quarter. Samjo Management LLC boosted its stake in MDxHealth by 130.9% in the 4th quarter. Samjo Management LLC now owns 1,824,312 shares of the company's stock valued at $4,324,000 after buying an additional 1,034,312 shares in the last quarter. Oppenheimer & Co. Inc. raised its stake in shares of MDxHealth by 100.0% in the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company's stock valued at $47,000 after acquiring an additional 10,000 shares during the last quarter. Finally, AWM Investment Company Inc. raised its position in shares of MDxHealth by 11.1% during the fourth quarter. AWM Investment Company Inc. now owns 4,721,290 shares of the company's stock worth $11,189,000 after acquiring an additional 471,290 shares during the last quarter.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.